ReviewArteriosclerosis, thrombosis, and vascular biology2025
Alcohol, Liver Disease, and Peripheral Arterial Disease: Epidemiology, Mechanisms, and Clinical Implications.
Review in Arteriosclerosis, thrombosis, and vascular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Identification of risk factors for the progression of age-related macular degeneration: a systematic review and meta-analysis of cohort studies.Frontiers in medicine · 2025Pooled it
- Soluble endoglin as a marker of clinically significant portal hypertension in patients with cirrhosis.Scientific reports · 2026Article
- Alcohol Consumption and DNA Methylation in a Mediterranean Cohort: A Focus on Oxidative Stress and Aging Biomarkers.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Peripheral arterial disease (PAD) is a major vascular complication associated with significant morbidity and mortality. While traditional cardiovascular risk factors such as smoking, hypertension, and diabetes are well established, emerging evidence suggests that alcohol consumption, alcoholic liver disease, and metabolic-associated steatotic liver disease may also contribute to PAD risk. This review synthesizes current epidemiological evidence linking alcohol intake, alcoholic liver disease, and metabolic-associated steatotic liver disease to PAD and explores potential mechanisms, including atherosclerosis, endothelial dysfunction, chronic inflammation, dyslipidemia, and coagulation abnormalities. Observational studies suggest a possible protective effect of light-to-moderate alcohol consumption though genetic studies challenge this notion. In addition, alcoholic liver disease and metabolic-associated steatotic liver disease are increasingly recognized as contributors to systemic vascular dysfunction and PAD progression. In conclusion, given the rising burden of liver disease, it is crucial to determine whether PAD screening is warranted in patients with high-risk alcoholic liver disease and metabolic-associated steatotic liver disease. Addressing modifiable risk factors and optimizing pharmacological interventions may help mitigate PAD risk. Future research should focus on longitudinal studies, sex- and ethnicity-specific differences, and omics-based approaches to refine risk prediction, early detection, and targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.